After a Two-Year Buying Spree, Invitrogen Aims to Consolidate Pieces Through Realignment Plan | GenomeWeb

After a buying spree over the past two years that brought in a wide array of businesses and technologies, Invitrogen is realigning its divisions in an attempt to better serve its customer base and accelerate the firm's revenue growth, Chairman and CEO Greg Lucier said this week.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.